Cyclacel Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Cyclacel Pharmaceuticals, Inc.
The companies announced data from their Phase II/III study in children aged 5-11 and intend to take them to regulators to expand Comirnaty's authorization; also, an expert panel advising India's drug regulator endorsed plans for a Phase III trial of a single-dose Russian vaccine, Sputnik Light, and vaccines from other Indian firms progress.
Before the month is out, Alvotech hopes to hear back from the US FDA for its AVT02 high-concentration 100mg/ml biosimilar adalimumab candidate. The Icelandic firm, which remains embroiled in litigation with originator AbbVie, has reported top-line results from its key switching study.
Lilly hopes to address immunology and pain indications with biotech’s LYTAC technology. Sunovion licenses European rights to Parkinson’s therapy Kynmobi to Bial.
Alvotech and Natco have failed to persuade a US court that certain of AbbVie’s IP shielding its Imbruvica blockbuster is invalid. In response, the originator said that it did not anticipate generic competition to its branded oral therapy for treating forms of cancer until March 2032, assuming pediatric exclusivity is granted.
- Other Names / Subsidiaries
- Xcyte Therapies
- ALIGN Pharmaceuticals